| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/24/2013 | WO2013012959A1 Novel compositions and methods for treating prostate cancer |
| 01/24/2013 | WO2013012954A2 Resorption enhancers as additives to improve the oral formulation of non-anticoagulant sulfated polysaccharides |
| 01/24/2013 | WO2013012918A1 Heterocyclic compounds and uses thereof |
| 01/24/2013 | WO2013012915A1 Heterocyclic compounds and uses thereof |
| 01/24/2013 | WO2013012909A1 Kinase inhibitor with improved aqueous solubility |
| 01/24/2013 | WO2013012892A2 Treatments for diabetes mellitus and obesity |
| 01/24/2013 | WO2013012848A1 Benzamides |
| 01/24/2013 | WO2013012844A1 Arylpyrazole ethers as inhibitors of leukotriene a4 hydrolase |
| 01/24/2013 | WO2013012829A1 Diaminocyclohexane compounds and uses thereof |
| 01/24/2013 | WO2013012827A1 Diaminocyclohexane compounds and uses thereof |
| 01/24/2013 | WO2013012806A2 Protection of cells from alu-rna-induced degenereation and inhibitors for protecting cells |
| 01/24/2013 | WO2013012783A1 Method for timing a colonoscopy wherein a picosulate composition is administered |
| 01/24/2013 | WO2013012760A1 Compositions and methods for modulating metabolic pathways |
| 01/24/2013 | WO2013012758A1 Methods for the synthesis of functionalized nucleic acids |
| 01/24/2013 | WO2013012737A1 New natural and synthetic compounds for treating cancer and other diseases |
| 01/24/2013 | WO2013012723A1 Novel 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors |
| 01/24/2013 | WO2013012715A1 Methods for treating inflammation |
| 01/24/2013 | WO2013012692A1 Pharmaceutical compositions comprising plant-based polysaccharides and uses thereof |
| 01/24/2013 | WO2013012681A1 Tricyclic inhibitors of kinases useful for the treatment of proliferative diseases |
| 01/24/2013 | WO2013012670A1 Treatment for hypoxia |
| 01/24/2013 | WO2013012665A2 Permanent attachment of pigments and dyes to surfaces containing calkyl-oh functionality |
| 01/24/2013 | WO2013012662A2 Pharmaceutical compositions for rectal administration |
| 01/24/2013 | WO2013012649A1 Azaindole compounds and methods for treating hiv |
| 01/24/2013 | WO2013012644A1 2-methylene-20(21)-dehydro-19,24,25,26,27,-pentanor-vitamin d analogs |
| 01/24/2013 | WO2013012485A2 Novel crystalline forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| 01/24/2013 | WO2013012326A1 Tablet containing dehydroepiandrosterone (dhea) |
| 01/24/2013 | WO2013012307A1 Method for manufacturing a pharmaceutical composition in the form of extended-release tablets containing pirfenidone and use thereof in the regression of chronic renal insufficiency, breast capsular contracture and hepatic fibrosis in humans |
| 01/24/2013 | WO2013012199A1 Capsule formulation comprising montelukast and levocetirizine |
| 01/24/2013 | WO2013012135A1 Pre-freeze dried azacitidine preparation, freeze dried azacitidine preparation and method of manufacturing the same |
| 01/24/2013 | WO2013012118A1 Novel phenylester compound and pharmaceutical compositions for preventing or treating inflammatory diseases comprising the same |
| 01/24/2013 | WO2013012117A1 Pharmaceutical compositions for preventing or treating inflammatory diseases, comprising phytosterol compound |
| 01/24/2013 | WO2013012049A1 Heart failure preventing agent |
| 01/24/2013 | WO2013012007A1 Anti-virus agent composition |
| 01/24/2013 | WO2013011932A1 Azabenzimidazole derivative having ampk-activating activity |
| 01/24/2013 | WO2013011858A1 Tetravalent platinum complex and pharmaceutical composition containing same |
| 01/24/2013 | WO2013011841A1 Indirubin derivative having highly selective cytotoxicity for malignant tumors |
| 01/24/2013 | WO2013011536A1 Intranasal administration of agents with pro-inflammatory activity for the therapy of neurological disorders |
| 01/24/2013 | WO2013011506A1 Modified platinum compounds |
| 01/24/2013 | WO2013011489A1 Adenine derivatives having immunomodulating anti-inflammatory and analgesic activity |
| 01/24/2013 | WO2013011477A1 Pharmaceutical invention of tapentadol |
| 01/24/2013 | WO2013011461A1 Process for the preparation of asenapine maleate |
| 01/24/2013 | WO2013011458A1 A method of managing chemotherapy induced alopecia or cachexia or both |
| 01/24/2013 | WO2013011402A1 Gpr 119 modulators |
| 01/24/2013 | WO2013011285A1 Azetidine derivatives for treatment of melanin related disorders |
| 01/24/2013 | WO2013011238A1 Novel haemostatic composition |
| 01/24/2013 | WO2013011216A1 Boiled sugar sweet comprising non-fructosylated α-galactooligosaccharides |
| 01/24/2013 | WO2013011157A1 Method for preparation of medetomidine with chloroacetone |
| 01/24/2013 | WO2013011135A1 Ceramide c16-cer and cers6 in the treatment and diagnosis of multiple sclerosis (ms) |
| 01/24/2013 | WO2013011098A1 Imino-sugar c-glycosides, preparation and use thereof |
| 01/24/2013 | WO2013011033A1 3-(fluorvinyl)pyrazoles and the use thereof |
| 01/24/2013 | WO2013011019A1 Pharmaceutical composition for treating a respiratory disease |
| 01/24/2013 | WO2013010964A1 Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
| 01/24/2013 | WO2013010963A1 Use of coumarin derivatives for the preparation of drugs for treating skin diseases |
| 01/24/2013 | WO2013010950A1 PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS, THEIR PREPARATION AND USE AS SIGMA LIGANDS |
| 01/24/2013 | WO2013010942A1 Composition and method for treating hpv |
| 01/24/2013 | WO2013010916A1 Salts of aza-bicyclic di-aryl ethers and methods to make them or their precursors |
| 01/24/2013 | WO2013010915A1 Intravaginal delivery system |
| 01/24/2013 | WO2013010904A1 Novel substituted indole derivatives as gamma secretase modulators |
| 01/24/2013 | WO2013010881A1 NEW CRTh2 ANTAGONISTS |
| 01/24/2013 | WO2013010880A1 New crth2 antagonists |
| 01/24/2013 | WO2013010869A1 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides btk-inhibitors |
| 01/24/2013 | WO2013010868A1 4 - imidazopyridazin- 1 -yl-benzamides and 4 - imidazotriazin- 1 - yl - benzamides as btk- inhibitors |
| 01/24/2013 | WO2013010839A1 Novel and selective ccr2 antagonists |
| 01/24/2013 | WO2013010780A1 Pharmaceutical composition for treating a metabolic syndrome |
| 01/24/2013 | WO2013010737A1 Patch containing diclofenac and thiocolchicoside |
| 01/24/2013 | WO2013010679A1 Salts of aza-bicyclic di-aryl ethers and methods to make them or their precursors |
| 01/24/2013 | WO2013010573A1 Compounds with matrix-metalloproteinase inhibitory activity |
| 01/24/2013 | WO2013010502A1 Acid addition salt of prasugrel, preparation method therefor and use thereof |
| 01/24/2013 | WO2013010453A1 Chemoking receptor antagonists |
| 01/24/2013 | WO2013010400A1 Compounds based on ibuprofen, preparation methods, uses and pharmaceutical preparation thereof |
| 01/24/2013 | WO2013010382A1 Heterocyclic substituted pyrimidine compound |
| 01/24/2013 | WO2013010380A1 Btk inhibitors |
| 01/24/2013 | WO2013010256A1 Combination treatment for cancer |
| 01/24/2013 | WO2013010241A1 Pharmaceutical composition for the treatment of arterial hypertension, based on the co-administration of anti-hypertensive agents and angiotensin (1-7) or another mas receptor agonist |
| 01/24/2013 | WO2013010238A1 Microparticle pharmaceutical compositions containing antiparasitics for prolonged subcutaneous therapy, use of the pharmaceutical compositions for producing a medicament, and method for treating parasitoses |
| 01/24/2013 | WO2013010218A1 Inhibition of clathrin |
| 01/24/2013 | WO2013010210A1 Oral compositions comprising an antacid, an anaesthetic and an inorganic matrix comprising silicon dioxide and titanium dioxide |
| 01/24/2013 | WO2012166923A3 Drug loaded polymeric nanoparticles and methods of making and using same |
| 01/24/2013 | WO2012164138A3 Combined compositions and preparations of sunitinib and l-carnitine |
| 01/24/2013 | WO2012164103A3 Blockers of the nogo-a s1pr pathway for the treatment of diseases characterized by neuronal damage and lack of subsequent repair |
| 01/24/2013 | WO2012163088A3 Medicine for treating kidney and heart disease and the uses thereof |
| 01/24/2013 | WO2012159092A3 Medical food for cognitive decline |
| 01/24/2013 | WO2012158942A9 Drug treatment of overactive bladder |
| 01/24/2013 | WO2012158880A3 Anaplastic thyroid cancers harbor novel oncogenic mutations of the alk gene |
| 01/24/2013 | WO2012158552A3 2'-fluoro-6'-methylene carbocyclic nuceosides and methods of treating viral infections |
| 01/24/2013 | WO2012154956A3 Anxiolytic effect of pterostilbene |
| 01/24/2013 | WO2012153071A3 Functionalized polysaccharides |
| 01/24/2013 | WO2012151252A3 Composition and method for treatment of diabetes |
| 01/24/2013 | WO2012149393A9 Tolerogenic synthetic nanocarriers for antigen-specific deletion of t effector cells |
| 01/24/2013 | WO2012148247A3 Pharmaceutical composition containing oleanolic acid acetate as an active ingredient for preventing or treating tlr- or il-6-mediated diseases |
| 01/24/2013 | WO2012148246A3 A preparation method of sitagliptin |
| 01/24/2013 | WO2012131341A3 Tight junctions modulators |
| 01/24/2013 | WO2012120356A3 Process for the preparation of (s)-(+)-or (r)-(-)-10 hydroxy dihydrodibenz[b,f]azepines by enantioselective reduction of 10, 11-dihydro-10-oxo-5h-dibenz[b,f]azepines and polymorphs thereof |
| 01/24/2013 | WO2012112699A3 Method and apparatus for the delivery of photo-chemical (cross-linking) treatment to corneal tissue |
| 01/24/2013 | WO2012103226A3 Bendamustine formulations |
| 01/24/2013 | WO2012099952A3 Benzofuro[3,2-c] pyridines and related analogs as serotonin sub-type 6 (5-ht6) modulators for the treatment of obesity, metabolic syndrome, cognition and schizophrenia |
| 01/24/2013 | WO2012097371A3 Chemical inhibitors of cholesterol biosynthesis and venous angiogenesis |
| 01/24/2013 | WO2012096494A9 Agent containing b-ring-substituted flavonoid derivatives for treating arthritis |
| 01/24/2013 | WO2012038988A8 Electrolyte fortifying composition for recharge, a hydrating supplement, and process for preparing the same |
| 01/24/2013 | WO2012021287A9 Methods for the treatment and prevention of metabolic disorders |